Gemlapodect

Gemlapodect
Clinical data
Other namesNOE-105; NOE105
Routes of
administration		Oral
Drug classPhosphodiesterase PDE10A inhibitor
Identifiers
  • 1-methyl-4-(morpholine-4-carbonyl)-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)pyrazole-5-carboxamide
CAS Number
PubChem CID
DrugBank
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC22H21N7O3
Molar mass431.456 g·mol−1
3D model (JSmol)
  • CN1C(=C(C=N1)C(=O)N2CCOCC2)C(=O)NC3=CC4=NC(=NN4C=C3)C5=CC=CC=C5
  • InChI=1S/C22H21N7O3/c1-27-19(17(14-23-27)22(31)28-9-11-32-12-10-28)21(30)24-16-7-8-29-18(13-16)25-20(26-29)15-5-3-2-4-6-15/h2-8,13-14H,9-12H2,1H3,(H,24,30)
  • Key:MMCSMWHWVGGCGL-UHFFFAOYSA-N

Gemlapodect (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name NOE-105) is a phosphodiesterase PDE10A inhibitor which is under development for the treatment of Tourette's syndrome and speech disorders. It is taken orally. The drug is thought to work by modulating dopaminergic signaling in the striatum through PDE10A inhibition in medium spiny neurons. Gemlapodect was originated by Roche and is under development by Noema Pharma. As of September 2025, it is in phase 2 clinical trials for both Tourette's syndrome and speech disorders.

See also

References

  1. 1 2 3 4 5 "Noema Pharma". AdisInsight. 18 September 2025. Retrieved 2 June 2026.
  2. 1 2 3 "Delving into the Latest Updates on Gemlapodect with Synapse". Synapse. 10 March 2026. Retrieved 2 June 2026.
  3. 1 2 Häge A, Krämer R, Dunlap M, Mechler K, Müller-Vahl KR, Nagy P (June 2025). "Emerging therapeutic approaches for Tourette syndrome and other tic disorders - a systematic review of current clinical trials". European Child & Adolescent Psychiatry. 34 (6): 1719–1729. doi:10.1007/s00787-024-02637-x. PMID 39714607.